USFDA grants orphan drug and pediatric exclusivities for Cresemba for aspergillosis and mucormycosis in children
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Subscribe To Our Newsletter & Stay Updated